Literature DB >> 21414119

Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis.

A A Boudreault1, H Xie, R M Rakita, J D Scott, C L Davis, M Boeckh, A P Limaye.   

Abstract

BACKGROUND: Cytomegalovirus (CMV) disease occurs frequently after cessation of antiviral prophylaxis in CMV-seronegative kidney transplant recipients from seropositive donors (D+R-), and the risk factors are incompletely defined.
METHOD: We retrospectively assessed the incidence, clinical features, and risk factors for CMV disease in a cohort of D+R- kidney transplant recipients who received antiviral prophylaxis at a single US transplant center using descriptive statistics and Cox proportional hazards models.
RESULTS: CMV disease developed in 29 of 113 (26%) D+R- patients at a median of 185 days (interquartile range 116-231 days) post transplant, including CMV syndrome (66%) and tissue invasive disease (34%). The incidence of CMV disease was higher in patients who underwent re-transplantation (57% vs. 24%) and this factor was independently associated with a higher risk of CMV disease in multivariable analysis (hazard ratio, 4.02; 95% confidence interval, 1.3-13; P = 0.016). Other demographic and transplant variables were not independently associated with a risk of late-onset CMV disease.
CONCLUSIONS: Despite a comprehensive analysis of patient and transplant variables, only re-transplantation was identified as a risk factor for CMV disease in D+R- kidney transplant recipients who received antiviral prophylaxis, but had limited clinical predictive value. The development of novel laboratory markers to identify patients at greatest risk for CMV disease should be a priority for future studies.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21414119      PMCID: PMC3148074          DOI: 10.1111/j.1399-3062.2011.00624.x

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  14 in total

1.  Decreased incidence of cytomegalovirus infection in thymoglobulin-treated transplant patients with 6 months of valganciclovir prophylaxis.

Authors:  Enver Akalin; Jonathan S Bromberg; Vinita Sehgal; Scott Ames; Barbara Murphy
Journal:  Am J Transplant       Date:  2004-01       Impact factor: 8.086

2.  Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR.

Authors:  Michael Boeckh; MeeiLi Huang; James Ferrenberg; Terry Stevens-Ayers; Laurence Stensland; W Garrett Nichols; Lawrence Corey
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

3.  Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis.

Authors:  Ajit P Limaye; Ramasamy Bakthavatsalam; Hyung W Kim; Sara E Randolph; Jeffrey B Halldorson; Patrick J Healey; Christian S Kuhr; Adam E Levy; James D Perkins; Jorge D Reyes; Michael Boeckh
Journal:  Transplantation       Date:  2006-06-27       Impact factor: 4.939

4.  Repeat organ transplantation in the United States, 1996-2005.

Authors:  J C Magee; M L Barr; G P Basadonna; M R Johnson; S Mahadevan; M A McBride; D E Schaubel; A B Leichtman
Journal:  Am J Transplant       Date:  2007       Impact factor: 8.086

5.  Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation.

Authors:  Supha K Arthurs; Albert J Eid; Rachel A Pedersen; Walter K Kremers; Fernando G Cosio; Robin Patel; Raymund R Razonable
Journal:  Clin Infect Dis       Date:  2008-03-15       Impact factor: 9.079

6.  24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course.

Authors:  Alden M Doyle; Karen M Warburton; Simin Goral; Emily Blumberg; Robert A Grossman; Roy D Bloom
Journal:  Transplantation       Date:  2006-04-27       Impact factor: 4.939

7.  International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology.

Authors:  K Solez; R A Axelsen; H Benediktsson; J F Burdick; A H Cohen; R B Colvin; B P Croker; D Droz; M S Dunnill; P F Halloran
Journal:  Kidney Int       Date:  1993-08       Impact factor: 10.612

8.  American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation.

Authors:  A Humar; M Michaels
Journal:  Am J Transplant       Date:  2006-02       Impact factor: 8.086

9.  Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis.

Authors:  Enver Akalin; Vinita Sehgal; Scott Ames; Sabera Hossain; Lisa Daly; Murphy Barbara; Jonathan S Bromberg
Journal:  Am J Transplant       Date:  2003-06       Impact factor: 8.086

10.  Prospective follow-up of primary CMV infections after 6 months of valganciclovir prophylaxis in renal transplant recipients.

Authors:  Ilkka Helanterä; Irmeli Lautenschlager; Petri Koskinen
Journal:  Nephrol Dial Transplant       Date:  2008-10-08       Impact factor: 5.992

View more
  9 in total

1.  Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment.

Authors:  Elena Beam; Raymund R Razonable
Journal:  Curr Infect Dis Rep       Date:  2012-12       Impact factor: 3.725

2.  Accuracy of Inpatient International Classification of Diseases, Ninth Revision, Clinical Modification Coding for Cytomegalovirus After Kidney Transplantation.

Authors:  C A Q Santos; D C Brennan; M A Olsen
Journal:  Transplant Proc       Date:  2015 Jul-Aug       Impact factor: 1.066

3.  Update on cytomegalovirus infections of the gastrointestinal system in solid organ transplant recipients.

Authors:  Tracy L Lemonovich; Richard R Watkins
Journal:  Curr Infect Dis Rep       Date:  2012-02       Impact factor: 3.725

4.  Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.

Authors:  Nina Singh; Drew J Winston; Raymund R Razonable; G Marshall Lyon; Fernanda P Silveira; Marilyn M Wagener; Terry Stevens-Ayers; Bradley Edmison; Michael Boeckh; Ajit P Limaye
Journal:  JAMA       Date:  2020-04-14       Impact factor: 56.272

5.  Delayed-onset cytomegalovirus disease coded during hospital readmission after kidney transplantation.

Authors:  Carlos A Q Santos; Daniel C Brennan; Victoria J Fraser; Margaret A Olsen
Journal:  Transplantation       Date:  2014-07-27       Impact factor: 4.939

6.  Impaired direct priming of CD8 T cells by donor-derived cytomegalovirus following kidney transplantation.

Authors:  Shazia Shabir; Baksho Kaul; Annette Pachnio; Gemma D Banham; Helen Smith; Sourabh Chand; Seema Jham; Lorraine Harper; Simon Ball; Afsar Rahbar; Cecilia Söderberg-Nauclér; Paul Moss; Richard Borrows
Journal:  J Am Soc Nephrol       Date:  2013-07-11       Impact factor: 10.121

7.  Pharmacoepidemiology of cytomegalovirus prophylaxis in a large retrospective cohort of kidney transplant recipients with Medicare Part D coverage.

Authors:  Carlos A Q Santos; Daniel C Brennan; Mohammed J Saeed; Victoria J Fraser; Margaret A Olsen
Journal:  Clin Transplant       Date:  2016-03-04       Impact factor: 2.863

8.  Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience.

Authors:  Linda A Selvey; Wai H Lim; Peter Boan; Ramyasuda Swaminathan; Claudia Slimings; Amy E Harrison; Aron Chakera
Journal:  BMC Infect Dis       Date:  2017-07-17       Impact factor: 3.090

9.  Impacts of Interleukin-18 Polymorphisms on the Incidence of Delayed-Onset Cytomegalovirus Infection in a Cohort of Kidney Transplant Recipients.

Authors:  Isabel Pérez-Flores; Jose Luis Santiago; Cristina Fernández-Pérez; Elena Urcelay; María Ángeles Moreno de la Higuera; Natividad Calvo Romero; Beatriz Rodríguez Cubillo; Ana Isabel Sánchez-Fructuoso
Journal:  Open Forum Infect Dis       Date:  2019-07-20       Impact factor: 3.835

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.